Mellor R, Lancaster K, Ritter A. Systematic review of untreated remission from alcohol problems: estimation lies in the eye of the beholder. J Subst Abuse Treat. 2019 Jul;102:60-72. doi: 10.1016/j.jsat.2019.04.004
Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study. J Subst Abuse Treat. 2019 Mar;110:1-8. doi: 10.1016/j.jsat.2019.11.004
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Cohen JT, Marino RJ, Sacco P, Terrin N. Association between the functional independence measure following spinal cord injury and long-term outcomes. Spinal Cord. 2012 Oct;50(10):728-33. doi: 10.1038/sc.2012.50
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.